Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project aims to accelerate discovery and validation of blood-based biomarkers for neurodegenerative diseases. Data generated will be openly accessible through the National Alzheimer’s Coordinating Center, supporting AI-driven research and a national data competition. This initiative could significantly enhance understanding of disease mechanisms and improve diagnosis and treatment development.
Nvidia has surpassed Apple in the holdings of every S&P 500 index fund, reflecting a significant change in investment trends within these funds. This shift highlights growing investor confidence in Nvidia's growth potential and the tech sector's evol...
Micron has committed to investing $10 billion over the next decade to build a new research laboratory, with construction starting in 2027. This significant investment highlights Micron's focus on advancing technology and innovation in its field. The ...
Solana's cryptocurrency price surged above $94 after briefly touching $102, marking a 25% increase in one week. Much of the activity is driven by derivatives, with futures trading volume at $19.33 billion compared to $1.88 billion on the spot market,...
Trinity Capital (TRIN) showed strong performance with a record $619 million in Q2 fundings and 36% growth in assets under management, supported by disciplined underwriting and low non-accruals indicating solid credit quality. The company offers a 12%...
The Sandbox identified and contained a vulnerability in its cross-chain bridge on Base and BNB Smart Chain that allowed an attacker to mint unbacked SAND tokens. The incident affected less than 0.01% of the total 3 billion SAND supply, with no user w...
